Literature DB >> 3855286

Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors.

P M Moy, E C Holmes, S H Golub.   

Abstract

We assessed natural killer activity of lymphocytes present at the site of human tumors to determine the local effects of the tumor on immune function. Lymphocytes were extracted from human pulmonary tumors of varying histological types. In addition to tumor-infiltrating lymphocytes (TIL), peripheral blood lymphocytes from the same patients were prepared. Using a Michaelis-Menten kinetic model and titration of K562 targets in a 51Cr release assay, TIL exhibited a marked depression of maximal lytic capacity (Vmax) when compared to autologous peripheral blood lymphocytes. In a single cell lysis and binding assay to assess the proportion of target-binding lymphocytes and target-lysing binders, both TIL and peripheral blood lymphocytes had equivalent numbers of lymphocytes binding target cells and an equivalent number of target-binding cells that could mediate cytolysis. Analysis of lymphocyte subsets was performed using mouse monoclonal antibodies. The TIL population expressed markers found on natural killer cells, including HNK-1 and B73.1. Thus, natural killer cells are present at the tumor site, show lytic capability, but appear to be unable to recycle for multiple lytic events.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855286

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats.

Authors:  T Matsuzaki; N Murase; A Yagihashi; H Shinozuka; Y Shimizu; T Furuya; N Burrell; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1992-04       Impact factor: 1.066

Review 2.  Bronchoalveolar lavage and the immunology of lung cancer.

Authors:  G Semenzato; M Spatafora; C Feruglio; E Pace; V Dipietro
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype.

Authors:  E Lotzová; C A Savary; R S Freedman; C L Edwards; M Morris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.

Authors:  M Radrizzani; C Gambacorti-Passerini; G Parmiani; G Fossati
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  The human NK cell--a short over-view and an hypothesis on NK recognition.

Authors:  M Jondal
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

6.  Tumor infiltrating lymphocytes of spontaneous versus transplanted mouse mammary tumors.

Authors:  W Z Wei; G H Heppner
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Lymphokine production by human melanoma tumor-infiltrating lymphocytes.

Authors:  M A Salmeron; T Morita; H Seki; C D Platsoucas; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Cytotoxic activity and T cell receptor repertoire in tumor-infiltrating lymphocytes of adrenal cell carcinomas.

Authors:  Y Yamamoto; K Backlin; H Nakagomi; E Halapi; C Juhlin; A Bucht; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

10.  Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

Authors:  E Halapi; Y Yamamoto; C Juhlin; M Jeddi-Tehrani; J Grunewald; R Andersson; C Hising; G Masucci; H Mellstedt; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.